ArticleClinical and experimental hepatology2021
Prevalence and prognostic value of cirrhotic cardiomyopathy as defined according to the proposed new classification.
Article in Clinical and experimental hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cirrhotic cardiomyopathy: a systematic review and meta-analysis of prevalence across various diagnostic approaches.Annals of Saudi medicinePooled it
- Cirrhotic cardiomyopathy: pathophysiology, assessment, and implications for liver transplantation.Therapeutic advances in gastroenterology · 2026Review
- Cirrhotic Cardiomyopathy: Bridging Hepatic and Cardiac Pathophysiology in the Modern Era.Journal of clinical medicine · 2025Review
- [Cirrhotic cardiomyopathy – Clinically fact or academic curiosity? Review: Part 1: definition, epidemiology, pathology and clinical manifestations]Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina) · 2024Article
- The Contemporary Role of Speckle Tracking Echocardiography in Cirrhotic Cardiomyopathy.Life (Basel, Switzerland) · 2024Review
- Cardiomyopathy in cirrhosis: From pathophysiology to clinical care.JHEP reports : innovation in hepatology · 2024Review
- How non-alcoholic fatty liver disease and cirrhosis affect the heart.Hepatology international · 2023Review
- Markers of cardiac injury in patients with liver cirrhosis.Croatian medical journal · 2023Review
- Dysregulated Calcium Handling in Cirrhotic Cardiomyopathy.Biomedicines · 2023Review
- Impact of Cirrhotic Cardiomyopathy Diagnosed According to Different Criteria on Patients with Cirrhosis Awaiting Liver Transplantation: A Retrospective Cohort Study.Digestive diseases and sciences · 2022Article
- Pathogenic Mechanisms Underlying Cirrhotic Cardiomyopathy.Frontiers in network physiology · 2022Review
- LTSI Consensus Guidelines: Preoperative Cardiac Evaluation in Adult Liver Transplant Recipients.Journal of clinical and experimental hepatologyReview
- Update on cirrhotic cardiomyopathy: from etiopathogenesis to treatment.Annals of gastroenterologyReview
- Cardiac dysfunction in patients of cirrhosis of the liver and its correlation with Child-Pugh score: A cross-sectional study at a tertiary care center in Northern India.International journal of critical illness and injury scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aim of the studyPrevalence and prognostic relevance of cirrhotic cardiomyopathy (CCM), as defined according to the new core criteria proposed in 2019, are still unknown. We investigated this relevant issue in a large cohort of cirrhotic patients. MATERIAL AND
methodsWe retrospectively interrogated a data set of 162 collected cirrhotic patients followed up for at least 6 years, who underwent standard Doppler echocardiography and were compared with 46 healthy subjects. Left ventricular (LV) geometry, systo-diastolic function, global longitudinal strain and the main hemodynamic parameters were assessed according to current guidelines. Systolic dysfunction was diagnosed if LV ejection fraction (LVEF) ≤ 50% and/or global longitudinal strain (GLS) < 18% or > 22%.
resultsAdequate echocardiographic images permitting speckle tracking analysis were available in 83 patients. No patient presented LVEF ≤ 50%, GLS < 18% or > 22% was evident in 25%, advanced diastolic dysfunction was evident in 10%. Overall the prevalence of CCM was 29%. Patients with and without CCM presented similar clinical, biochemical, hemodynamic and echocardiographic features at baseline and similar incidence of death or type 1 hepatorenal syndrome at follow-up.
conclusionsAccording to the new criteria CCM is detected in 29%, mainly due to altered GLS at rest, but without prognostic relevance and therefore useless for the clinical management of cirrhotic patients. We propose to modify the criteria by removing the LVEF assessment and adding also a stress test assessing the cardiac contractile reserve to distinguish patients with a blunted cardiac response, which could present a worst prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.